Related Experiment Videos
Monoclonal antibodies--why should surgeons be interested?
1Cross Cancer Institute, Department of Surgery, Edmonton, Alberta, Canada.
Materia Medica Polona. Polish Journal of Medicine and Pharmacy
|October 1, 1992
Summary
Radioimmunoguided surgery enhances colorectal cancer treatment by using labeled antibodies to detect hidden tumors during surgery. This technique improves cancer resection and may reduce recurrence rates, potentially improving patient survival.
Area of Science:
- Oncology
- Surgical Innovation
- Radiopharmaceutical Applications
Background:
- Monoclonal antibodies are tumor-specific and can be radiolabeled.
- Immunoscintigraphy shows promise for cancer detection but often lacks confirmation.
- Colorectal cancer surgery can benefit from advanced diagnostic techniques.
Purpose of the Study:
- To evaluate radioimmunoguided surgery (RIGS) as an adjunctive technique for colorectal cancer.
- To assess the sensitivity and specificity of RIGS in detecting subclinical tumors.
- To explore the potential of RIGS in improving surgical outcomes and reducing recurrence.
Main Methods:
- Utilizing radiolabeled monoclonal antibodies for intraoperative tumor detection.
- Comparing RIGS findings with operative and histologic confirmations.
- Analyzing sensitivity and specificity data from clinical studies.
Main Results:
- RIGS demonstrates high sensitivity (70-100%) and specificity (66-100%) in colorectal cancer surgery.
- Subclinical tumors were identified in approximately one-third of patients.
- RIGS provided valuable intraoperative information for complete cancer resection.
Conclusions:
- Radioimmunoguided surgery is a promising adjunctive technique for colorectal cancer.
- It has the potential to decrease local recurrence rates, especially for rectosigmoid tumors.
- RIGS may significantly alter surgical approaches and improve patient survival in colorectal cancer treatment.